New: Q3 2025 Market Report Available

Market intelligence for
Priority Review Vouchers

The definitive platform for tracking FDA PRV issuances, secondary market transactions, and regulatory shifts. Real-time data for biopharma investors and executives.

Access Dashboard View Methodology
Total Market Value
$2.8B+
Aggregate disclosed transaction volume
2018 2025
+2 this month
108
Vouchers Issued
Avg Price
$95M
Last Reported Sale

Program Architecture

Comprehensive tracking across all four FDA priority review voucher pathways.

RPD Active

Rare Pediatric Disease

Incentivizes drugs for serious rare diseases affecting fewer than 200,000 individuals under age 18.

TD Active

Tropical Disease

Targets specific infectious diseases that disproportionately affect developing countries.

MTMC Active

Medical Countermeasure

For drugs preventing or treating harm from biological, chemical, radiological, or nuclear agents.

CNPV New 2025

National Priority

Accelerated 1-2 month review for products addressing urgent national health priorities.

Transaction Stream

Date Sponsor / Transferor Product Program Status
2025-11-12 Novo Nordisk Inc. Wegovy CNPV REDEEMED
2025-10-05 Regeneron DB-OTO CNPV UNUSED
2025-08-22 Jazz Pharmaceuticals Mudoyso RPD PENDING
2025-04-15 Abeona Therapeutics Zevasakyn RPD SOLD ($105M)
2025-02-01 Bavarian Nordic A/S Vinuulnya TD SOLD ($95M)

Latest Intelligence

REGULATORY

FDA Launches CNPV Program

The Commissioner's National Priority Voucher drastically reduces review times to 1-2 months for critical health priorities.

MARKET DATA

Q2 2025 Sales Analysis

Transaction volume stabilizes near $100M as inventory tightens. Deep dive into secondary market liquidity.

LEGISLATION

RPD Sunset Clause Update

Congressional committee moves to extend the Rare Pediatric Disease program through 2028.

Start tracking the market

Get instant alerts on issuances, sales, and SEC filings. Join top biopharma analysts relying on PRV Watch.